Predicting accrual achievement: Monitoring accrual milestones of NCI-CTEP-sponsored clinical trials

Clinical Cancer Research

Volumn 17, Issue 7, 2011, Pages 1947-1955

  Cheng, Steven K ^a   Dietrich, Mary S ^b   Dilts, David M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCRUAL ACHIEVEMENT; ARTICLE; CANCER RESEARCH; CLINICAL TRIAL (TOPIC); HEALTH CARE CONCEPTS; PATIENT PARTICIPATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; RESEARCH PRIORITY; RESEARCH SUBJECT; UNITED STATES;

CLINICAL TRIALS AS TOPIC; HUMANS; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; PATIENT SELECTION; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 79953327697     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1730     Document Type: Article

References (18)

1. Institute of Medicine. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. Washington, DC: Institute of Medicine of the National Academies; 2010.
2. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004;291:2720-6. (Pubitemid 38725421)
3. Cheng SK, Dietrich MS, Dilts DM. A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of Cancer Therapy Evaluation Program (NCI-CTEP) sponsored studies. Clin Cancer Res 2010;16:5557-63.
4. Emanuel EJ, Schnipper LE, Kamin DY, Levinson J, Lichter AS. The costs of conducting clinical research. J Clin Oncol 2003;21:4145-50. (Pubitemid 46606182)
5. Waldinger M. Cost-out. In: Institute of Medicine: Multi-site Clinical Trials and NCI Cooperative Groups. Washington, DC: Institute of Medicine; 2008.
6. Carter RE, Sonne SC, Brady KT. Practical considerations for estimating clinical trial accrual periods: application to a multi-center effectiveness study. BMC Med Res Methodol 2005;5:11.
7. Wittes RE, Friedman MA. Accrual to clinical trials. J Natl Cancer Inst 1988;80:884-5.
8. Abrams JS, Murgo A, Christian MC. NCI's Cancer Therapy Evaluation Program: a commitment to treatment trials. Cancer Treat Res 2007;132:31-50.
9. Ansher SS, Scharf R. The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute: industry collaborations in new agent development. Ann N Y Acad Sci 2001;949:333-40. (Pubitemid 34059998)
10. Surveillance Epidemiology and End Results. National Cancer Institute. Available from: http://seer.cancer.gov/[cited 2008 Aug 30].
11. Korn EL, Freidlin B, Mooney M, Abrams JS. Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007. J Clin Oncol 2010;28:5197-201.
12. Cancer Therapy Evaluation Program (CTEP): development of early stopping guidelines for slow accruing trials. Available from: http://ctep.cancer.gov/ protocol/development/docs/slow-accrual-guidelines-dev.pdf [cited 2010].
13. Cooper R. Winning at New Products. Reading, MA: Addison-Wesley; 1990.
14. Dilts DM, Cheng SK, Crites JS, Sandler AB, Doroshow JH. Phase III clinical trial development: a process of chutes and ladders. Clin Cancer Res 2010;16:5381-9.
15. Dilts DM, Sandler A, Cheng S, Crites J, Ferranti L, Wu A, et al. Development of clinical trials in a cooperative group setting: the Eastern Cooperative Oncology Group. Clin Cancer Res 2008;14:3427-33.
16. Dilts DM, Sandler AB. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. J Clin Oncol 2006;24:4545-52. (Pubitemid 46630949)
17. Dilts DM, Sandler AB, Baker M, Cheng SK, George SL, Karas KS, et al. Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. J Clin Oncol 2006;24:4553-7. (Pubitemid 46630950)
18. Schroen AT, Petroni GR. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials 2010;7:312-21.